- Home
- CYCN vs PRPO Comparison
CYCN vs PRPO Comparison
Compare CYCN & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCN
- PRPO
- Stock Information
- Founded
- CYCN 2018
- PRPO N/A
- Country
- CYCN United States
- PRPO United States
- Employees
- CYCN N/A
- PRPO N/A
- Industry
- CYCN Biotechnology: Pharmaceutical Preparations
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- CYCN Health Care
- PRPO Industrials
- Exchange
- CYCN Nasdaq
- PRPO Nasdaq
- Market Cap
- CYCN 8.4M
- PRPO 9.9M
- IPO Year
- CYCN N/A
- PRPO N/A
- Fundamental
- Price
- CYCN $4.19
- PRPO $6.61
- Analyst Decision
- CYCN
- PRPO
- Analyst Count
- CYCN 0
- PRPO 0
- Target Price
- CYCN N/A
- PRPO N/A
- AVG Volume (30 Days)
- CYCN 5.7M
- PRPO 8.1K
- Earning Date
- CYCN 03-04-2025
- PRPO 03-28-2025
- Dividend Yield
- CYCN N/A
- PRPO N/A
- EPS Growth
- CYCN N/A
- PRPO N/A
- EPS
- CYCN N/A
- PRPO N/A
- Revenue
- CYCN $194,000.00
- PRPO $17,411,000.00
- Revenue This Year
- CYCN N/A
- PRPO $75.18
- Revenue Next Year
- CYCN N/A
- PRPO N/A
- P/E Ratio
- CYCN N/A
- PRPO N/A
- Revenue Growth
- CYCN N/A
- PRPO 31.31
- 52 Week Low
- CYCN $1.27
- PRPO $4.31
- 52 Week High
- CYCN $9.47
- PRPO $7.25
- Technical
- Relative Strength Index (RSI)
- CYCN 59.43
- PRPO 61.42
- Support Level
- CYCN $2.81
- PRPO $6.30
- Resistance Level
- CYCN $6.25
- PRPO $6.90
- Average True Range (ATR)
- CYCN 0.57
- PRPO 0.25
- MACD
- CYCN 0.19
- PRPO 0.03
- Stochastic Oscillator
- CYCN 47.85
- PRPO 83.33
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.